ARALEZ PHARMACEUTICALS US INC.

Lobbying Spend

—

Filings

Firms Hired

Active Period

2016–2017

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2017	—	4	1
2016	—	4	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
BAKER & HOSTETLER LLP	—	8

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	6
SENATE	6

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	7
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	1

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 34114th Congress

21st Century Cures Act

2016 · fourth_quarter · Firm: BAKER & HOSTETLER LLP

Cited source text and reported amounts

H.R. 34, the 21st Century Cures Act, specifically policy issues relating to combination pharmaceutical products

Client expense: — · Firm income: $30,000

Matched citations: H.R. 34

H.R. 6114th Congress

21st Century Cures Act

2016 · third_quarter · Firm: BAKER & HOSTETLER LLP

Cited source text and reported amounts

H.R. 6, the 21st Century Cures Act, specifically policy issues relating to combination pharmaceutical products

Client expense: — · Firm income: $30,000

Matched citations: H.R. 6

H.R. 6114th Congress

21st Century Cures Act

2016 · second_quarter · Firm: BAKER & HOSTETLER LLP

Cited source text and reported amounts

H.R. 6, the 21st Century Cures Act, specifically policy issues relating to combination pharmaceutical products

Client expense: — · Firm income: $10,000

Matched citations: H.R. 6

ARALEZ PHARMACEUTICALS US INC. — Lobbying Disclosure | Poliscope